Clinical trial · Observational
Evaluation of Treatment Efficacy by Circulating Tumor Cell Phenotype Surveillance in Breast Cancer Patients
Surveillance of Circulating Tumor Cell Phenotype in Early Stage Breast Cancer Patients With Neoadjuvant Chemotherapy or Adjuvant Chemotherapy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The phenotype of circulating tumor cells (CTCs) is supposed to be significant indicator that is correlated the prognosis of breast cancer patients who have completed neoadjuvant chemotherapy, primary tumor surgery with/without adjuvant chemotherapy. The aim of this observational study is to assess the efficacy of CTCs surveillance in predicting the prognosis of breast cancer patients.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Neoplasms | Breast Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Chemotherapy Effect | — | UNRESOLVED | — |
| Neoplastic Cells, Circulating | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CTC detection | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Breast cancer patients
- interventionNames
- Diagnostic Test: CTC detection
Primary outcomes (1)
- measure
- iDFS
- timeFrame
- From date of enrollment through study completion, up to 10 years.
- description
- The survival time from the date of tumor resection to the date of the relapse of the invasive disease.
Secondary outcomes (2)
- measure
- overall survival
- timeFrame
- From date of enrollment through study completion, up to 10 years.
- description
- The survival time from the date of recruitment to the date of death.
- measure
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria * The age is more than 18 years old; * Pathology confirmed malignant breast tumor; * No clinical diagnosis of other malignancies, unstable complications or uncontrolled infection; * Life expectancy is greater than 6 month; * The main organ function is normal; * The subjects volunteered to participate in this study, signed informed consent, followed up with good compliance. Exclusion Criteria * Patients who had suffered from other malignant tumors; * With uncontrolled bacterial, viral or fungal infections; * With physical or mental disorders * Without or limited civil capacity; * Infected with human immunodeficiency virus (HIV)； * Circumstances in which the investigator considers it inappropriate to participate in this study.
References
Publications (0)
Data not yet available